media – Page 5 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Pharmaron grants technology license to shareholder Juno; Shiyao Group Enters into Exclusive License Agreement | Pharmaceutical Early Ginseng

NO.1 Shiyao Group enters into exclusive license agreement for irinotecan liposome injection On May 15th, Shiyao Group announced that it has entered into an exclusive license agreement with Cipla USA, Inc. for the commercialization of irinotecan liposome injection in the United States. According to the terms, the group will receive a down payment of $15 million and is also entitled to receive up to $25 million in potential initial commercial sales and regulatory milestone payments, as well as up to $1.025 billion in potential additional commercial sales milestone payments, and a double-digit gradient sales commission calculated based on the annual net sales of the product in the region. Comment: This event is an important breakthrough in the company’s internationalization strategy. The potential transaction volume of over 1 billion US dollars demonstrates the huge commercial potential of Irinotecan Liposome Injection in the US market, and also reflects the strong strength of ...
- Source: drugdu
- 40
- May 19, 2025
In the first quarter, BeiGene reduced losses and accelerated the commercialization of innovative drugs

BeiGene Limited (referred to as “BeiGene”, 688235. SH) recently released its Q1 2025 financial report, which showed that the company’s operating revenue reached 8.048 billion yuan, an increase of 50.2% compared to the same period last year’s 5.359 billion yuan. In terms of net profit, the company still faces certain pressure to incur losses, but the losses have significantly narrowed. The net profit attributable to the parent company was a loss of 94.503 million yuan, a significant reduction from the loss of 1.908 billion yuan in the same period last year. From the perspective of cost structure, BeiGene continues to increase its research and development investment. Data shows that BeiGene’s research and development expenses in 2024 amounted to 14.14 billion yuan, an increase of 10.35% compared to the same period last year. Research and development investment is used for preclinical studies, clinical trials, collaborative research and development of the company’s ...
- Source: drugdu
- 36
- May 19, 2025
【EXPERT Q&A】Are imported drugs really more effective than domestic ones? Why?

Drugdu.com expert’s response: Imported drugs are not absolutely more effective than domestic drugs. The difference in their efficacy is influenced by multiple factors, including drug type, research and development (R&D) technology, formulation processes, and individual patient variations. A comprehensive assessment based on specific circumstances is necessary. Below is a detailed analysis: I. The Difference in Drug Efficacy is Not Absolute Common Diseases: For common illnesses such as colds and coughs, there is little difference in efficacy between domestic and imported drugs. For example, domestic paracetamol has been widely recognized for its antipyretic and analgesic effects and is more cost-effective. Chronic Diseases: In the treatment of chronic diseases requiring long-term medication, such as hypertension and diabetes, imported drugs may offer better patient compliance due to their precise formulations and superior side effect management. However, domestic drugs that have passed consistency evaluations are equally reliable in terms of efficacy and safety. Complex ...
- Source: drugdu
- 62
- May 19, 2025
How Can Pharmaceutical Exporters Secure Their First Overseas Distributor?— A Practical Guide from Sourcing to Evaluation and Negotiation

In the field of pharmaceutical foreign trade, finding a suitable overseas distributor is often the most direct and effective way to penetrate a new national or regional market. However, for companies that are new to export, questions like “How do I find a distributor?”, “How can I assess if they are trustworthy?”, and “How do I maintain control during negotiations?” can be daunting. This article offers a hands-on guide to help pharmaceutical exporters navigate the entire process—from zero to one—and take their first step in global channel development. 1. Define the Type of Distributor You Need Different products and markets require different types of distributors. Before you start the search, align your internal team on the following key points: Do you need an exclusive distributor, or are you open to multi-distributor models? Do you require specific channel types (hospitals, retail pharmacies, e-commerce, wholesalers)? Will you need the ...
- Source: drugdu
- 50
- May 16, 2025
Trump signs executive order to lower prescription drug prices, expected to have limited short-term impact

According to a research report by CITIC Securities, on May 12th, Trump signed an executive order titled “Providing Most Favored Nation Prices for Prescription Drugs to American Patients,” aimed at lowering prescription drug prices in the US market. Trump proposed “most favored nation” prices in the executive order, requiring pharmaceutical companies to sell their drugs in the United States at prices equal to the lowest prices in comparable developed countries. At the same time, Trump also proposed to increase the transparency of drug prices in the United States and reduce the profit margin of middlemen represented by PBM. CITIC Securities believes that the implementation of this administrative order is difficult and the short-term impact on the industry is expected to be limited. The full text is as follows Drugs and Innovation | Trump signs executive order to lower prescription drug prices, expected to have limited short-term impact On May 12, ...
- Source: drugdu
- 52
- May 16, 2025
Huasen Pharmaceutical plans to hold a controlling stake in Aorui Pharmaceutical to promote the development of innovative drugs in the fields of oncology and immunotherapy

On the evening of May 14th, Huasen Pharmaceutical announced that in order to integrate and supplement its innovative drug research and development pipeline, further strengthen its own innovative drug research and development capabilities, and accelerate transformation and upgrading, the company and its wholly-owned subsidiary – Chongqing Huasen Yingnuo Biotechnology Co., Ltd. (referred to as “Huasen Yingnuo”) and existing shareholders Yang Shengyong, Huang Qi, etc. of Chengdu Aorui Pharmaceutical Co., Ltd. (referred to as “Aorui Pharmaceutical”) have signed a “Equity Change Agreement”. Huasen Yingnuo will acquire 37.3619% equity of Aorui Pharmaceutical for free as compensation for the repurchase obligations of relevant shareholders in the historical transaction documents of the company and Huasen Yingnuo. After the completion of this equity transfer, in addition to the 28.6381% equity previously held by the company in Aorui Pharmaceutical, the company and its subsidiaries will hold a total of 66% equity in Aorui Pharmaceutical, which will ...
- Source: drugdu
- 51
- May 16, 2025
New Drug Combos Could Cut Heart Failure Mortality by 60%

Optimized treatment can reduce the mortality risk for chronic heart failure (HF) by as much as 60%. The role of appropriate drug combinations and rapid diagnosis was discussed at the 91st Annual German Society of Cardiovascular Medicine Annual Conference. “It is important to start drug treatment for HF immediately after diagnosis, in parallel with investigating the underlying causes, as the benefits of treatment appear very quickly,” said Birgit Assmus, MD, cardiologist and head of the Heart Failure Department of the University Hospital of Giessen and Marburg, Marburg, Germany. Recommended Treatment For HF with reduced ejection fraction (HFrEF) and a left ventricular ejection fraction (LVEF) ≤ 40%, as well as for HF with moderately reduced ejection fraction (LVEF between 41% and 49%), the 2021 European Society of Cardiology (ESC) guidelines recommend a quadruple combination of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor/neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose ...
- Source: drugdu
- 56
- May 16, 2025
GSK Makes a Big Liver Disease Move With $1.2B Deal for Phase 3-Ready MASH Drug

GSK is acquiring Boston Pharmaceuticals’ efimosfermin, which posted Phase 2 results showing improvement in fibrosis and resolution of MASH. GSK said this fusion protein will complement an siRNA drug it is currently developing for liver diseases. GSK is expanding its prospects in hepatology, paying $1.2 billion to acquire a drug that goes after a clinically validated liver target but with a dosing advantage that could give it a competitive edge against rivals further along in their development of therapies for the fatty liver disease MASH. The agreement announced Wednesday brings GSK efimosfermin alfa, a Boston Pharmaceuticals drug that is ready for Phase 3 testing. In addition to metabolic dysfunction-associated steatohepatitis (MASH), GSK plans to develop the drug for alcohol-related liver disease. Both are forms of steatotic liver disease, in which fat buildup damages the organ. MASH leads to inflammation and liver scarring, also called fibrosis. Though the history of ...
- Source: drugdu
- 51
- May 16, 2025
Shutaishen’s STSP-0601 for injection obtains drug production license

On May 13, Shutaishen, an announcement was issued that the company’s subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. (hereinafter referred to as “Beijietai”) recently obtained a drug production license issued by the Jiangsu Provincial Food and Drug Administration. The announcement stated that Beijietai has obtained the “Drug Production License” and will be commissioned to produce therapeutic biological products.(STSP-0601 for injection is limited to registration and application use) and is not expected to have a significant impact on the company’s current performance. The relevant products can only be commercially produced after obtaining the drug marketing approval number. https://finance.eastmoney.com/a/202505143404500613.html
- Source: drugdu
- 49
- May 16, 2025
Entered into an exclusive licensing agreement with Cipla for irinotecan liposome injection

CSPC Pharmaceutical Group announced on the Hong Kong Stock Exchange that it has entered into an exclusive license agreement with Cipla USA, Inc. (“Cipla”) for the commercialization of the company’s irinotecan liposome injection in the United States. Under the terms of the agreement, the company agreed to grant Cipla an exclusive license to commercialize the product in the region. The company will receive an initial payment of US$15 million and is also entitled to receive potential first commercial sales and regulatory milestone payments of up to US$25 million and potential additional commercial sales milestone payments of up to US$1.025 billion, as well as double-digit tiered sales commissions based on the product’s annual net sales in the region. Irinotecan is currently used to treat a variety of solid tumors, such as metastatic pancreatic cancer, colorectal cancer, lung cancer and cervical cancer, and is a component of a variety of combination therapies ...
- Source: drugdu
- 54
- May 16, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.